Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767794 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNATP53TSHR | |
| Hydrochloric Acid SCHEMBL9144470 | 0.76 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNATP53TSHR | |
| SCHEMBL15494272 | 0.75 | ALDH1A1 (0.40) | ALDH1A1MAPTLMNATP53TSHR | |
| Phosphoramide Mustard SCHEMBL3103104 | 0.74 | ALDH1A1 (0.68) | ALDH1A1LMNA | |
| Phosphoramide Mustard SCHEMBL12937644 | 0.74 | ALDH1A1 (0.68) | ALDH1A1LMNA | |
| SCHEMBL14626536 | 0.73 | ALDH1A1 (0.39) | ALDH1A1MAPT | |
| SCHEMBL12207961 | 0.73 | ALDH1A1 (0.43) | ALDH1A1MAPT | |
| Phosphoramide Mustard SCHEMBL8929440 | 0.72 | ALDH1A1 (0.66) | ALDH1A1LMNATP53TSHRHTT | |
| SCHEMBL2788515 | 0.72 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL4554018 | 0.70 | TP53 (0.39) | ALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167972-B1 | Enzyme catalyzed therapeutic agents | KIADIS PHARMA INTELLECTUAL PROPERTY B V (NL) | 2017-03-08 | — | — | EP | disclosed |
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8664204-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664204-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8507464-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507464-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7601703-B2 | Enzyme catalyzed therapeutic agents | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-13 | — | — | US | disclosed |
| US-7419968-B1 | Methods for treating therapy-resistant tumors | CELMED ONCOLOGY (USA), INC. (CA) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | ALDH1A1 1961/4885MAPT 4228/4885LMNA 3521/4885 |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | ALDH1A1 1961/4885MAPT 4228/4885LMNA 3521/4885 |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | ALDH1A1 1961/4885MAPT 4228/4885LMNA 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.